BRINGING CLINICIANS TOGETHER TO DISCUSS CURRENT DRUG THERAPY

May 2018 • Vol. 15, No. 5
The following succinct analysis appeared in Prescriber’s Letter. Based on vol. 25. No. 5

ANTITHROMBOTICS

New evidence will raise questions about the role of aspirin for venous thromboembolism (VTE) prophylaxis after hip or knee replacement.

We’re used to preventing VTE with an anticoagulant in these patients…and saving aspirin as a potentially less effective option.

But VTE risk with these surgeries is going down…due to newer techniques and post-op protocols that get patients up and moving early.

Now evidence suggests that switching to aspirin 81 mg/day after 5 days of the direct oral anticoagulant (DOAC) Xarelto (rivaroxaban) seems as effective as continuing Xarelto…with a similar bleeding risk.

This blended approach could be a game changer.

That’s because DOACs and low-molecular-weight heparins (LMWH) such as enoxaparin are pricey…and warfarin is tough to stabilize short-term.

Continue to start with a DOAC or LMWH for most patients.

Consider switching to aspirin 81 mg/day after about 5 days of anticoagulation. Higher aspirin doses don’t improve efficacy…but might increase bleeding.

So far, the evidence is after switching from Xarelto to aspirin…but it’s likely okay to use other DOACs or a LMWH before switching.

Stick with an anticoagulant for the entire course for patients at higher VTE risk…such as those with a prior VTE, CV disease, extremely limited mobility, or active cancer.

Save warfarin for prosthetic valve patients or CrCl below 30 mL/min.

Continue VTE prophylaxis for at least 10 to 14 days…and preferably up to 35 days, especially after hip replacement.

If you do switch patients to aspirin, educate them to start it when their next antiagulant dose would be due…and emphasize adherence.

Hear our team discuss all this with a thrombosis expert on PL Voices. And see our chart, VTE Prevention After Hip or Knee Replacement, for more about how meds stack up.

(For more on this topic, see Clinical Resource #340516 at PrescribersLetter.com.)


See LEADER NOTES for answers to discussion questions.
DISCUSSION QUESTIONS

OVERVIEW OF CURRENT THERAPY

1. What is known about the risk of venous thromboembolism (VTE) and VTE prevention following hip or knee replacement?

ANALYSIS OF NEW STUDY

2. What type of study was this? How were the patients selected for inclusion?

3. How were the study groups defined?

4. How were the outcomes evaluated?

5. What were the outcomes of this trial?

See LEADER NOTES for answers to discussion questions.
6. What were the strengths and weaknesses of this study?

7. Were the results expressed in terms we care about and can use?

HOW SHOULD THE NEW FINDINGS CHANGE CURRENT THERAPY?

8. Do the results change your practice? How?

APPLY THE NEW FINDINGS TO THE FOLLOWING CASE

M.A. is a 74-year-old male with a past medical history of gout, hypothyroidism, and bilateral knee osteoarthritis. He comes in today complaining of worsening knee pain that is significantly impacting his quality of life. He has been taking acetaminophen 650 mg QID for several months, but doesn’t feel that it provides him much relief. He misses being able to walk the dog and work in his garden. He wants to avoid surgery if possible and would like to understand his treatment options.

9. What are conservative treatment options for M.A.’s osteoarthritis?

See LEADER NOTES for answers to discussion questions.
You discuss the options with M.A. He doesn’t want to use a topical product because he is concerned it will be expensive and messy to use. He prefers trying an oral NSAID, but wants to know about the side effects of using an NSAID long-term.

10. What are the risks of long-term oral NSAIDs? What should you consider when choosing a chronic NSAID for M.A.?

You discuss the possible risks of long-term NSAIDs, and M.A. decides he would still like to try one. You start him on naproxen 500 mg BID since M.A. is concerned about cost. You also start M.A. on omeprazole 20 mg daily, to limit his risk of GI bleeding.

M.A. returns for follow-up six months later. He’s been taking naproxen as you recommended and is tolerating it well, but is still having significant pain. He has talked with an orthopedic surgeon about knee replacement surgery, and she mentioned that M.A. would need to take a medication afterward to prevent blood clots. M.A. is skeptical of the new blood thinner medications he’s seen on TV and wants to know your opinion.

11. What are M.A.’s options for post-op VTE prophylaxis? How long will M.A. likely need to continue VTE prophylaxis?

See LEADER NOTES for answers to discussion questions.
REFERENCES


Additional Prescriber’s Letter Resources available at PrescribersLetter.com


See LEADER NOTES for answers to discussion questions.
Journal Club Contributing Editors:

Lori Dickerson, PharmD, FCP, Editor; Jennifer Nieman, PharmD, BCPS, Associate Editor; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of South Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL.

Editors and Authors: Jeff Jellin, PharmD, Editor-in-Chief; Sherri Bohringer, PharmD, Senior Editor, VP Content; Karen Davidson, PharmD, Senior Editor Emeritus; Tammie Amenli, RPh, PharmD, Editor, Senior Director of Continuing Education & Content Management; Melissa Blair, PharmD, FASHP, FCP, BCPS; Sandye Chabot, PharmD; Lori Dickerson, PharmD, FCP; Rachel Maynard, PharmD; Kimberly Palaceo, PharmD, Editors; Stacy Hester, RPh, BCPS; Crystal Maric, BSc Pharm, MBA, ACPR-J Jennifer Nieman, PharmD, BCPS, Associate Editors; Bethany Bryant, PharmD, BCPS; Vickie Danaher, PharmD; Leslie Gingo, PharmD, BCPS; Flora Harp, PharmD; Tanner Higginbotham, PharmD; Jeff Langford, PharmD, BCPS-AQ Cardiology; Toni Ripley, PharmD, FCP, BCPS-AQ Cardiology, ASH-CHC; Brea Rowan, PharmD, BCPS; James Van, BSc Pharm; Don Weinberger, PharmD; Marlea Wellein, PharmD, BCPS, Assistant Editors; Karen Wilson, BA, Manuscript Editor; Minda Paglinawan, BA, Assistant Manuscript Editor; Jenni Mangrum, BS, CPhT, Assistant Education and Accreditation Editor, Mark Graber, MD, MSHEC, FACEP, Associate Clinical Editor. Consultants: Jill Allen, PharmD, BCPS; Melanie Cupp, PharmD, BCPS; John Greiss, BSc Pharm, JD, LLM; Katie Lacaria, BSc Pharm, ACPR; Heidi Liston, BSc Pharm, PharmD; Lu-Ann Murdoch, BSc Pharm; Annette Murray, BSc Pharm; Jennifer Pennington, RN, BSN. Editorial Advisors: Christopher Anslinger, PA-C; Thomas Baminger, MD, FAHA, FNA; Christopher Barry, PA-C, MMS; William Beedner, MD; Larissa Bosser, PharmD, BCPS; Robert Brown, MD, FAAP; Stephen Brunton, MD; Holley Bush, PharmD; Peter Carek, MD, MS; Gary Choy, PharmD; Matthew Cline, MD; John Connolly, MD, FACP, FCCP; Sandra Counts, PharmD; Hikmat Fikrat, PhD; Rex Force, PharmD, FCCP, BCPS; Lawrence Frank, MD, FACP; Peter Garbeff, MD; Mark Garofoli, PharmD, MSHCE, FACEP; Denise Gontiz, FNP-C; Charles Green, RPh; John Hambright, PharmD; Roland Hart, MD; Kyle Herbold, MD; Patricia Hatton, MD; Sydney Hendry, MD; Raissa Hill, DO; Jennifer Jones, MD; Sheela Kapre, MD, FACP, FCCP; Adam Kaye, PharmD, FASCP, FCPhA; William Kehoe, PharmD, MA, FCCP, BCPS; Joshua Lenchus, DO, RPh, FACP, SHIM; Stanley Leong, PharmD; Kevin Maeda, PharmD; Christine Marsh, RPh; Eric Matheson, MD; MS; Christina McGlaun, CPhT, EMT; Kay Niegli, RPh; Mike Pastrick, RPh; Emest Pieper, PharmD; Daren Primack, MD, FACC; Barbara Rankin, MD; Jenna Reel, PharmD, BCPS; CDE; George Rishwain, MD; Sandy Robertson, PharmD; Edward Rogen, PharmD, BCACP; Gerald Rubley, MSN, PharmD; Ruth Ruffe, PharmD; Annie Marie Santos, MD; David Schneider, MD; Allen Shaughnessy, PharmD, MMEd; Jonathan Sokota, PharmD, BCACP; Joshua Tessier, DO; Bruce Uch, PharmD; John David Williamson, MD, FAAP; Raymond Wong, MD; William Yee, PharmD, FASHP, FSCCP; Kent Yep, RPh.

Advisory Board: Evan Ballard, MD, Jonesville Family Medical Ctr; Melvin Baron, PharmD, MPA, Univ of Southern Calif; J Jan Basile, MD, FACP, Medical Univ of South Carolina; Kevin Brown, MD, FACOG, Texas AM; R. Keith Campbell, RPh, FADE, FASHP, FAPhA, CDE, Washington State Univ; Andrea Darby-Stewart, MD, HonorHealth; Anthony A. Donato, J, c, MD, MPH, Reading Health System; Jan Dutz, MD, Baylor College of Med; Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAAN, DCC, Fitzgerald Health Ed Associates; Barry Gidal, PharmD, RPh, Univ of Wisc; Robert Gotfried, DO, FAAFP; Martin Grajower, MD, FACP, BCPS; William Guglielmo, PharmD, UC San Francisco; Stuart Haines, PharmD, BCPS, BCACP, BC-ADM, FCCP, FASHP, FAPhA, Univ of Miss; Jeff Hammar, Jr, MD, Col USAF, MC, FS; B. Mark Hess, MD, FACP; John Holman, MD, MPH, FAAP; Eric Jackson, PharmD, FCCP, BCPS, Univ of Conn; Peter Jacobson, PhD, DDS, Univ of the Pacific; Paul Jensen, MD, PharmD, FAAFP; Alan David Kaye, MD, PhD, DABA, DABPM, DABIPP, Louisiana State Univ; Steve Kayser, PharmD, UC San Francisco; Brian Kessler, DO, FACOFP, Medical Univ of South Carolina; Craig D. Williams, PharmD, FNA, BCPS, Oregon Health & Science Univ.

DISCLOSURE: The editors of this activity and its publisher, Therapeutic Research Center, have no relevant financial interests related to the products or services covered by this activity. Therapeutic Research Center Prescriber’s Letter does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Prescriber’s Letter focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

Unbiased Evidence and Recommendations for the Prescriber on New Developments in Drug Therapy

3120 West March Lane, Stockton, CA 95219
TEL (209) 472-2240 ~ FAX (209) 472-2249
PrescribersLetter.com

The contents are copyrighted. © 2018 Therapeutic Research Center. All Rights Reserved.

See LEADER NOTES for answers to discussion questions.